ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2001
Perspectives on antiviral use during pandemic influenza.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 108 citations in OpenAlex.
- Polymorphism of BIK as a Host Risk Factor for Severe Influenza.DNA and cell biology · 2025Review
- BIK polymorphism and proteasome regulation unveil host risk factor for severe influenza.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Impact of Oseltamivir and Diabetes Development.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The multifarious roles of heterogeneous ribonucleoprotein A1 in viral infections.Reviews in medical virology · 2020Review
- Article
- Article
- iTRAQ-based quantitative proteomics reveals important host factors involved in the high pathogenicity of the H5N1 avian influenza virus in mice.Medical microbiology and immunology · 2017Article
- Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses.PloS one · 2017Article
- High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.PloS one · 2016Article
- Networks of Host Factors that Interact with NS1 Protein of Influenza A Virus.Frontiers in microbiology · 2016Article
- Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.Frontiers in cellular and infection microbiology · 2016Article
- Influenza virus-host interactomes as a basis for antiviral drug development.Current opinion in virology · 2015Review
- Influenza virus-host interactome screen as a platform for antiviral drug development.Cell host & microbe · 2014Article
- Modeling triple-diffusions of infectious diseases, information, and preventive behaviors through a metropolitan social network-An agent-based simulation.Applied geography (Sevenoaks, England) · 2014Article
- Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.PLoS computational biology · 2014Article
- A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.Scientific reports · 2013Article
- Pandemism of swine flu and its prospective drug therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Review
- Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.Journal of virology · 2012Article
- Coupling infectious diseases, human preventive behavior, and networks--a conceptual framework for epidemic modeling.Social science & medicine (1982) · 2012Article
- Replication-incompetent influenza A viruses that stably express a foreign gene.The Journal of general virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral agents could potentially play a major role in the initial response to pandemic influenza, particularly with the likelihood that an effective vaccine is unavailable, by reducing morbidity and mortality. The M2 inhibitors are partially effective for chemoprophylaxis of pandemic influenza and evidence from studies of interpandemic influenza indicate that the neuraminidase inhibitors would be effective in prevention. In addition to the symptom benefit observed with M2 inhibitor treatment, early therapeutic use of neuraminidase inhibitors has been shown to reduce the risk of lower respiratory complications. Clinical pharmacology and adverse drug effect profiles indicate that the neuraminidase inhibitors and rimantadine are preferable to amantadine with regard to the need for individual prescribing and tolerance monitoring. Transmission of drug-resistant virus could substantially limit the effectiveness of M2 inhibitors and the possibility exists for primary M2 inhibitor resistance in a pandemic strain. The frequency of resistance emergence is lower with neuraminidase inhibitors and mathematical modelling studies indicate that the reduced transmissibility of drug-resistant virus observed with neuraminidase inhibitor-resistant variants would lead to negligible community spread of such variants. Thus, there are antiviral drugs currently available that hold considerable promise for response to pandemic influenza before a vaccine is available, although considerable work remains in realizing this potential. Markedly increasing the quantity of available antiviral agents through mechanisms such as stockpiling, educating health care providers and the public and developing effective means of rapid distribution to those in need are essential in developing an effective response, but remain currently unresolved problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.